Raptor Pharmaceutical to Participate in Three Upcoming Investor Conferences in June

NOVATO, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. RPTP today announced that company management will participate in three upcoming investor conferences in June.

• Wells Fargo Healthcare Conference - Boston, June 17, 2014 at 8:50 a.m. EDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com
• JMP Securities Healthcare Conference – New York, June 25, 2014 at 9:30 a.m. EDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com
• Janney Capital Markets Healthcare Corporate Access Day – Boston, June 26, 2014, 8:00 a.m. to 4 p.m. EDT. Management will be available for one-on-one meetings with institutional investors.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic fatty liver disease, Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.